← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

ACAD logoACADIA Pharmaceuticals Inc.(ACAD)Earnings, Financials & Key Ratios

ACAD•NASDAQ
$21.48
$3.68B mkt cap·9.4× P/E·Price updated May 6, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryNeuroscience and Psychiatry Therapies
AboutACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.Show more
  • Revenue$1.07B+11.9%
  • EBITDA$139M-43.7%
  • Net Income$391M+72.7%
  • EPS (Diluted)2.29+68.4%
  • Gross Margin91.69%+0.3%
  • EBITDA Margin12.96%-49.7%
  • Operating Margin9.78%-59.4%
  • Net Margin36.49%+54.3%
  • ROE39.89%+2.6%
  • ROIC10.03%-77.8%
  • Debt/Equity0.04-40.1%
Technical→

ACAD Key Insights

ACADIA Pharmaceuticals Inc. (ACAD) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Excellent 3Y average ROE of 21.4%
  • ✓Strong 5Y sales CAGR of 19.4%

✗Weaknesses

  • ✗Low quality earnings: Net income not backed by cash flow

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

ACAD Price & Volume

ACADIA Pharmaceuticals Inc. (ACAD) stock price & volume — 10-year historical chart

Loading chart...

ACAD Growth Metrics

ACADIA Pharmaceuticals Inc. (ACAD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years165.75%
5 Years19.39%
3 Years27.48%
TTM11.87%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM72.66%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM68.38%

Return on Capital

10 Years-32.59%
5 Years-7.59%
3 Years10.2%
Last Year10.08%

ACAD Recent Earnings

ACADIA Pharmaceuticals Inc. (ACAD) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 5/12 qtrs (42%)
Q1 2026Latest
Feb 25, 2026
EPS
$1.60
Est $0.14
+1067.9%
Revenue
$284M
Est $293M
-3.0%
Q4 2025
Nov 5, 2025
EPS
$0.26
Est $0.14
+85.7%
Revenue
$279M
Est $293M
-4.8%
Q3 2025
Aug 6, 2025
EPS
$0.16
Est $0.14
+14.3%
Revenue
$265M
Est $262M
+1.0%
Q2 2025
May 7, 2025
EPS
$0.11
Est $0.10
+10.0%
Revenue
$244M
Est $239M
+2.2%
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q1 2026LatestFeb 25, 2026
$1.60vs $0.14+1067.9%
$284Mvs $293M-3.0%
Q4 2025Nov 5, 2025
$0.26vs $0.14+85.7%
$279Mvs $293M-4.8%
Q3 2025Aug 6, 2025
$0.16vs $0.14+14.3%
$265Mvs $262M+1.0%
Q2 2025May 7, 2025
$0.11vs $0.10+10.0%
$244Mvs $239M+2.2%
Based on last 12 quarters of dataView full earnings history →

ACAD Peer Comparison

ACADIA Pharmaceuticals Inc. (ACAD) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
INVA logoINVAInnoviva, Inc.Direct Competitor1.91B22.526.8218.52%118.91%46.47%0.23
AXSM logoAXSMAxsome Therapeutics, Inc.Direct Competitor11.46B222.63-60.5065.55%-26.59%-260.01%2.73
INTR logoINTRInter & Co, Inc.Direct Competitor2.54B7.8418.7027.12%12.37%1.31
PTCT logoPTCTPTC Therapeutics, Inc.Direct Competitor5.52B66.618.56114.51%39.44%
BIIB logoBIIBBiogen Inc.Product Competitor28.15B190.6821.591.39%13.92%7.55%0.38
ALKS logoALKSAlkermes plcProduct Competitor5.89B35.3224.70-5.25%9.78%8.82%0.04
SUPN logoSUPNSupernus Pharmaceuticals, Inc.Product Competitor2.96B51.45-75.668.63%-3.74%-2.73%0.04
JAZZ logoJAZZJazz Pharmaceuticals plcProduct Competitor14.34B228.57-39.144.88%0.66%0.71%1.26

Compare ACAD vs Peers

ACADIA Pharmaceuticals Inc. (ACAD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs INVA

Most directly comparable listed peer for ACAD.

Scale Benchmark

vs CVS

Larger-name benchmark to compare ACAD against a more recognizable public peer.

Peer Set

Compare Top 5

vs INVA, AXSM, INTR, PTCT

ACAD Income Statement

ACADIA Pharmaceuticals Inc. (ACAD) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Sales/Revenue124.9M223.81M339.08M441.75M484.14M517.24M726.44M957.8M1.07B
Revenue Growth %620.68%79.19%51.5%30.28%9.6%6.83%40.45%31.85%11.87%
Cost of Goods Sold13.06M18.33M19.6M20.55M19.14M10.17M45.73M81.84M89M
COGS % of Revenue10.46%8.19%5.78%4.65%3.95%1.97%6.3%8.54%8.31%
Gross Profit
111.84M▲ 0%
205.48M▲ 83.7%
319.48M▲ 55.5%
421.2M▲ 31.8%
465M▲ 10.4%
507.07M▲ 9.0%
680.71M▲ 34.2%
875.96M▲ 28.7%
982.51M▲ 12.2%
Gross Margin %89.54%91.81%94.22%95.35%96.05%98.03%93.7%91.46%91.69%
Gross Profit Growth %765.31%83.72%55.48%31.84%10.4%9.05%34.24%28.68%12.16%
Operating Expenses404.25M452.92M566.02M707.79M635.44M730.66M754.09M645.16M877.7M
OpEx % of Revenue323.66%202.37%166.93%160.22%131.25%141.26%103.81%67.36%81.91%
Selling, General & Admin255.06M265.76M325.64M388.66M396.03M369.09M402.47M488.43M548.89M
SG&A % of Revenue204.21%118.74%96.04%87.98%81.8%71.36%55.4%50.99%51.23%
Research & Development149.19M187.16M240.38M319.13M239.41M361.57M351.62M303.25M328.8M
R&D % of Revenue119.45%83.63%70.89%72.24%49.45%69.91%48.4%31.66%30.69%
Other Operating Expenses3.98M-1.84M00000-146.51M0
Operating Income
-292.41M▲ 0%
-247.44M▲ 15.4%
-246.54M▲ 0.4%
-286.59M▼ 16.2%
-170.44M▲ 40.5%
-223.6M▼ 31.2%
-73.38M▲ 67.2%
230.79M▲ 414.5%
104.81M▼ 54.6%
Operating Margin %-234.11%-110.56%-72.71%-64.87%-35.2%-43.23%-10.1%24.1%9.78%
Operating Income Growth %-7.18%15.38%0.36%-16.24%40.53%-31.19%67.18%414.52%-54.59%
EBITDA-289.7M-244.44M-243.78M-283.65M-167.09M-221.57M-67.83M246.68M138.9M
EBITDA Margin %-231.94%-109.22%-71.9%-64.21%-34.51%-42.84%-9.34%25.75%12.96%
EBITDA Growth %-6.9%15.62%0.27%-16.36%41.09%-32.6%69.39%463.69%-43.69%
D&A (Non-Cash Add-back)2.71M3M2.77M2.93M3.34M2.03M5.55M15.88M0
EBIT-292.41M-247.44M-246.54M-286.59M-170.44M-223.6M-73.38M84.28M138.9M
Net Interest Income4.13M5.35M11.16M6.61M591K6.61M17.23M25.46M31.72M
Interest Income4.13M5.35M11.16M6.61M591K6.61M17.23M25.46M31.72M
Interest Expense000000000
Other Income/Expense4.13M3.51M12.16M5.61M2.92M10.15M22.34M27.28M34.09M
Pretax Income
-288.28M▲ 0%
-243.94M▲ 15.4%
-234.38M▲ 3.9%
-280.97M▼ 19.9%
-167.52M▲ 40.4%
-213.44M▼ 27.4%
-51.04M▲ 76.1%
258.07M▲ 605.7%
138.9M▼ 46.2%
Pretax Margin %-230.81%-108.99%-69.12%-63.6%-34.6%-41.27%-7.03%26.94%12.96%
Income Tax1.12M1.26M876K611K351K2.53M10.25M31.62M-252.1M
Effective Tax Rate %-0.39%-0.51%-0.37%-0.22%-0.21%-1.19%-20.08%12.25%-181.49%
Net Income
-289.4M▲ 0%
-245.19M▲ 15.3%
-235.26M▲ 4.1%
-281.58M▼ 19.7%
-167.87M▲ 40.4%
-215.97M▼ 28.7%
-61.29M▲ 71.6%
226.45M▲ 469.5%
391M▲ 72.7%
Net Margin %-231.71%-109.56%-69.38%-63.74%-34.67%-41.76%-8.44%23.64%36.49%
Net Income Growth %-6.64%15.28%4.05%-19.69%40.38%-28.66%71.62%469.5%72.66%
Net Income (Continuing)-289.4M-245.19M-235.26M-281.58M-167.87M-215.97M-61.29M226.45M391M
Discontinued Operations000000000
Minority Interest000000000
EPS (Diluted)
-2.36▲ 0%
-1.94▲ 17.8%
-1.60▲ 17.5%
-1.79▼ 11.9%
-1.05▲ 41.3%
-1.34▼ 27.6%
-0.37▲ 72.4%
1.36▲ 467.6%
2.29▲ 68.4%
EPS Growth %-0.85%17.8%17.53%-11.88%41.34%-27.62%72.39%467.57%68.38%
EPS (Basic)-2.36-1.94-1.60-1.79-1.05-1.34-0.371.372.32
Diluted Shares Outstanding122.6M126.58M147.2M157.33M160.49M161.68M163.82M166.36M171.36M
Basic Shares Outstanding122.6M126.58M147.2M157.33M160.49M161.68M163.82M165.72M169.34M
Dividend Payout Ratio---------

ACAD Balance Sheet

ACADIA Pharmaceuticals Inc. (ACAD) balance sheet — assets, liabilities & shareholders' equity

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Total Current Assets373.48M526.11M760.25M717.62M617.82M507.94M616.13M938.32M1.06B
Cash & Short-Term Investments341.34M473.52M697.43M631.96M520.71M416.82M438.87M755.99M819.69M
Cash Only69.42M134.76M189.68M326.03M147.44M114.85M188.66M319.59M177.69M
Short-Term Investments271.92M338.76M507.75M305.93M373.27M301.98M250.21M436.4M641.99M
Accounts Receivable18.43M27.79M37.87M50.28M65.34M63.08M102.35M104.69M148.23M
Days Sales Outstanding53.8645.3240.7741.5549.2644.5151.4339.950.49
Inventory5.25M4.07M6.34M9.68M7.88M6.64M35.82M21.95M34.67M
Days Inventory Outstanding146.6781.04118.1171.97150.28238.26285.8997.89142.19
Other Current Assets000000000
Total Non-Current Assets11.03M14.1M22.93M65M82.3M79.88M132.83M249.44M502.08M
Property, Plant & Equipment2.66M3.31M12.7M56.44M66.31M61.59M56.47M50.79M54.87M
Fixed Asset Turnover46.92x67.64x26.69x7.83x7.30x8.40x12.86x18.86x19.53x
Goodwill000000000
Intangible Assets5.54M4.06M2.58M1.11M0065.49M119.78M108.89M
Long-Term Investments2.48M4.83M7.09M7.07M012.97M5.77M07.84M
Other Non-Current Assets2.83M6.72M557K378K15.98M5.31M5.1M78.87M80.6M
Total Assets
384.51M▲ 0%
540.2M▲ 40.5%
783.18M▲ 45.0%
782.62M▼ 0.1%
700.12M▼ 10.5%
587.81M▼ 16.0%
748.96M▲ 27.4%
1.19B▲ 58.6%
1.56B▲ 31.7%
Asset Turnover0.32x0.41x0.43x0.56x0.69x0.88x0.97x0.81x0.69x
Asset Growth %-31.48%40.49%44.98%-0.07%-10.54%-16.04%27.41%58.59%31.69%
Total Current Liabilities49.03M59.56M74.83M105.97M96.07M125.63M254.25M394.87M277.11M
Accounts Payable8.79M3.17M7.22M8.49M6.88M12.75M17.54M16.19M10.9M
Days Payables Outstanding245.5563.06134.51150.85131.12457.63140.0272.2144.72
Short-Term Debt003.43M5.09M009.4M011.63M
Deferred Revenue (Current)000000000
Other Current Liabilities21.39M33.52M31.76M52.46M25.9M49.51M92.31M36.55M254.58M
Current Ratio7.62x8.83x10.16x6.77x6.43x4.04x2.42x2.38x3.83x
Quick Ratio7.51x8.76x10.08x6.68x6.35x3.99x2.28x2.32x3.71x
Cash Conversion Cycle-45.0263.324.3662.6668.43-174.86197.365.57147.97
Total Non-Current Liabilities191K1.56M9.22M49.64M63.16M61.77M62.95M60.09M59.69M
Long-Term Debt000000000
Capital Lease Obligations006.36M44.46M56.13M52.7M47.8M42.04M40.55M
Deferred Tax Liabilities000000000
Other Non-Current Liabilities191K1.56M2.86M5.18M7.03M9.07M15.15M18.06M19.14M
Total Liabilities49.22M61.12M84.05M155.61M159.23M187.4M317.2M454.96M336.81M
Total Debt009.79M49.55M64.43M62M57.2M51.99M52.19M
Net Debt-69.42M-134.76M-179.88M-276.48M-83M-52.85M-131.45M-267.59M-125.51M
Debt / Equity--0.01x0.08x0.12x0.15x0.13x0.07x0.04x
Debt / EBITDA-------0.21x0.38x
Net Debt / EBITDA--------1.08x-0.90x
Interest Coverage---------
Total Equity
335.29M▲ 0%
479.08M▲ 42.9%
699.13M▲ 45.9%
627.01M▼ 10.3%
540.89M▼ 13.7%
400.41M▼ 26.0%
431.75M▲ 7.8%
732.79M▲ 69.7%
1.23B▲ 67.5%
Equity Growth %-35.32%42.89%45.93%-10.32%-13.73%-25.97%7.83%69.72%67.49%
Book Value per Share2.733.784.753.993.372.482.644.407.16
Total Shareholders' Equity335.29M479.08M699.13M627.01M540.89M400.41M431.75M732.79M1.23B
Common Stock12K14K15K16K16K16K16K16K16K
Retained Earnings-1.22B-1.47B-1.7B-1.99B-2.15B-2.37B-2.43B-2.2B-1.81B
Treasury Stock000000000
Accumulated OCI-399K-372K297K36K-192K-975K24K292K1.45M
Minority Interest000000000

ACAD Cash Flow Statement

ACADIA Pharmaceuticals Inc. (ACAD) cash flow — operating, investing & free cash flow history

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Cash from Operations-217.86M-167.47M-151.13M-136.17M-125.66M-114.03M16.7M157.72M109.84M
Operating CF Margin %-174.42%-74.83%-44.57%-30.82%-25.96%-22.05%2.3%16.47%10.25%
Operating CF Growth %-3.54%23.13%9.76%9.9%7.72%9.25%114.65%844.31%-30.36%
Net Income-289.4M-245.19M-235.26M-281.58M-167.87M-215.97M-61.29M226.45M391M
Depreciation & Amortization2.71M3M2.77M2.93M3.34M2.03M5.55M15.88M11.76M
Stock-Based Compensation75.53M81.56M82.27M84.42M63.62M68.2M66.42M67.05M0
Deferred Taxes0002.75M0000-249.88M
Other Non-Cash Items-287K1.35M-4.61M44.28M75K-6.28M-12.12M-155.82M46.71M
Working Capital Changes-6.41M-8.2M3.71M11.04M-24.82M37.99M18.13M4.16M-89.76M
Change in Receivables-11.44M-8.75M-9.69M-12.47M-16.12M2.26M-39.27M-2.35M-43.54M
Change in Inventory-1.01M1.93M-1.74M-3.32M-4.21M2.42M-28.81M-49.55M-18.2M
Change in Payables4.87M-5.62M4.05M1.27M-1.62M5.87M4.8M-1.35M-5.29M
Cash from Investing92.47M-71.49M-165.84M192.51M-71.1M73.24M32M-30.54M-302.56M
Capital Expenditures-812K-2.15M-1.13M-7.59M-1.12M0-40.05M-523K-103.53M
CapEx % of Revenue0.65%0.96%0.33%1.72%0.23%-5.51%0.05%9.66%
Acquisitions044K164.71M-200.1M69.98M0-32.05M00
Investments---------
Other Investing93.28M44K-164.71M200.1M-69.98M032.05M146.51M0
Cash from Financing31.19M306.65M371.85M81M18.16M8.2M25.13M6.84M49.88M
Debt Issued (Net)000000000
Equity Issued (Net)31.19M306.65M371.85M81M18.16M8.2M25.13M6.84M49.88M
Dividends Paid000000000
Share Repurchases000000000
Other Financing000000000
Net Change in Cash
-94.2M▲ 0%
67.69M▲ 171.9%
54.88M▼ 18.9%
137.33M▲ 150.2%
-178.59M▼ 230.0%
-32.59M▲ 81.8%
73.81M▲ 326.5%
133.93M▲ 81.5%
-141.89M▼ 205.9%
Free Cash Flow
-218.67M▲ 0%
-169.62M▲ 22.4%
-152.26M▲ 10.2%
-143.75M▲ 5.6%
-126.78M▲ 11.8%
-114.03M▲ 10.1%
-23.35M▲ 79.5%
157.2M▲ 773.3%
105.15M▼ 33.1%
FCF Margin %-175.07%-75.79%-44.9%-32.54%-26.19%-22.05%-3.21%16.41%9.81%
FCF Growth %0.57%22.43%10.23%5.59%11.81%10.05%79.53%773.27%-33.11%
FCF per Share-1.78-1.34-1.03-0.91-0.79-0.71-0.140.940.61
FCF Conversion (FCF/Net Income)0.75x0.68x0.64x0.48x0.75x0.53x-0.27x0.70x0.28x
Interest Paid000000000
Taxes Paid1.37M1.26M1.6M1.11M1.04M2.19M5.85M19.52M0

ACAD Key Ratios

ACADIA Pharmaceuticals Inc. (ACAD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric2016201720182019202020212022202320242025
Return on Equity (ROE)-75.58%-67.8%-60.22%-39.93%-42.47%-28.75%-45.89%-14.73%38.89%39.89%
Return on Invested Capital (ROIC)-90.45%-70.67%-60.83%-42.82%-49.42%-31.62%-41.64%-16.99%45.22%10.03%
Gross Margin74.58%89.54%91.81%94.22%95.35%96.05%98.03%93.7%91.46%91.69%
Net Margin-1565.94%-231.71%-109.56%-69.38%-63.74%-34.67%-41.76%-8.44%23.64%36.49%
Debt / Equity---0.01x0.08x0.12x0.15x0.13x0.07x0.04x
FCF Conversion0.78x0.75x0.68x0.64x0.48x0.75x0.53x-0.27x0.70x0.28x
Revenue Growth28311.48%620.68%79.19%51.5%30.28%9.6%6.83%40.45%31.85%11.87%

ACAD SEC Filings & Documents

ACADIA Pharmaceuticals Inc. (ACAD) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 6, 2026·SEC

Material company update

Mar 5, 2026·SEC

Material company update

Feb 25, 2026·SEC

10-K Annual Reports

2
FY 2025

Feb 27, 2025·SEC

FY 2024

Feb 28, 2024·SEC

10-Q Quarterly Reports

6
FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 7, 2025·SEC

FY 2025

May 8, 2025·SEC

ACAD Frequently Asked Questions

ACADIA Pharmaceuticals Inc. (ACAD) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

ACADIA Pharmaceuticals Inc. (ACAD) reported $1.07B in revenue for fiscal year 2025. This represents a 24749% increase from $4.3M in 2000.

ACADIA Pharmaceuticals Inc. (ACAD) grew revenue by 11.9% over the past year. This is steady growth.

Yes, ACADIA Pharmaceuticals Inc. (ACAD) is profitable, generating $391.0M in net income for fiscal year 2025 (36.5% net margin).

Dividend & Returns

ACADIA Pharmaceuticals Inc. (ACAD) has a return on equity (ROE) of 39.9%. This is excellent, indicating efficient use of shareholder capital.

ACADIA Pharmaceuticals Inc. (ACAD) generated $105.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More ACAD

ACADIA Pharmaceuticals Inc. (ACAD) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.